Department of Hypertension, Angiology, and Internal Disease, Poznan University of Medical Sciences, Poznan, Poland.
Kardiol Pol. 2018;76(2):388-395. doi: 10.5603/KP.a2017.0215. Epub 2017 Nov 13.
Cardiovascular (CV) diseases remain a leading global cause of death. Lowering blood pressure (BP) reduces the risk of CV complications, especially stroke and acute coronary events, and it delays the progression of kidney disease. Adequate non-pharmacological treatment improves the effectiveness of the antihypertensive therapy. A Mediterranean diet with high content of vegetables (rich in tomatoes) is associated with a reduced CV risk.
The main objective of the present study was to assess whether the addition of standardised tomato extract (STE) or acetylsalicylic acid (ASA) to standard antihypertensive therapy can improve BP control in patients with arterial hypertension (HT).
The study involved 82 high-risk hypertensive patients. Patients with primary HT at high to a very high total CV risk were randomised in a blinded fashion to one of two groups, i.e. the ASA and STE group. The patients had two visits, a baseline visit and one after four weeks of treatment. In all the patients, during each visit, clinical BP and ambulatory BP measurements (ABPM) were performed. Platelet aggregation was determined using the VerifyNow analyser.
After four weeks of treatment in the STE group, there was a statistically significant reduction in 24-h systolic BP, diastolic BP, and mean arterial pressure values measured in ABPM (p < 0.001). After four weeks of treatment in the STE group there was a statistically significant reduction in pulse pressure (PP) during the daytime and during 24 h (p < 0.05). Interestingly, it was found that the use of STE in obese patients significantly decreased the day PP (p < 0.05). After four weeks of treatment in the ASA group there was no statistically significant reduction in BP values measured in ABPM.
The results of this study show that the addition of STE to standard antihypertensive therapy improves BP control in hypertensive patients with high CV risk. This effect, together with the anti-aggregatory effect, may indicate the pleiotropic effect of tomato extract. This fact justifies further research into functional foods and gives new insights into STE as a food supplement that could have new therapeutic and prophylactic uses for the treatment of hypertensive patients with high CV risk and especially with obesity.
心血管疾病仍然是全球主要的死亡原因。降低血压可降低心血管并发症的风险,尤其是中风和急性冠脉事件的风险,并可延缓肾脏疾病的进展。充分的非药物治疗可提高降压治疗的效果。富含蔬菜(富含番茄)的地中海饮食与降低心血管风险相关。
本研究的主要目的是评估在标准降压治疗的基础上添加标准化番茄提取物(STE)或乙酰水杨酸(ASA)是否可以改善高血压(HT)患者的血压控制。
该研究纳入了 82 例高危高血压患者。高至极高整体心血管风险的原发性 HT 患者被随机分为两组,即 ASA 和 STE 组。患者接受双盲治疗,每组患者均进行两次就诊,基线就诊和治疗 4 周后就诊。在所有患者中,每次就诊时均进行临床血压和动态血压测量(ABPM)。使用 VerifyNow 分析仪测定血小板聚集。
在 STE 组治疗 4 周后,ABPM 测量的 24 小时收缩压、舒张压和平均动脉压均有统计学意义的降低(p<0.001)。在 STE 组治疗 4 周后,日间和 24 小时的脉压(PP)有统计学意义的降低(p<0.05)。有趣的是,发现 STE 在肥胖患者中的应用可显著降低日间 PP(p<0.05)。在 ASA 组治疗 4 周后,ABPM 测量的血压值无统计学意义的降低。
本研究结果表明,在高心血管风险的高血压患者中,在标准降压治疗的基础上添加 STE 可改善血压控制。这种作用以及抗聚集作用可能表明番茄提取物的多效性。这一事实证明,对功能性食品进行进一步研究是合理的,并为 STE 作为一种食物补充剂提供了新的见解,这种补充剂可能为治疗高心血管风险的高血压患者,特别是肥胖患者提供新的治疗和预防用途。